Several different radiopharmaceuticals have been developed for imaging cell death, the most extensively studied being 99mTc-labelled Annexin V. Small human studies have demonstrated a significant correlation between tumour uptake following commencement of treatment and response to therapy [5, 7]. Here, ANXA5 is linked to neoplasm.